# Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family

> **NCT00779389** · PHASE1 · COMPLETED · sponsor: **University of Pittsburgh** · enrollment: 58 (actual)

## Conditions studied

- Head and Neck Cancer
- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Dasatinib + Placebo
- **DRUG:** Erlotinib plus Dasatinib
- **DRUG:** Placebo
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00779389
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779389, "Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00779389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*